Santen Pharmaceutical Co. Ltd. (Japan) and MacuSight Inc. (US) are to collaborate on developing MacuSight's sirolimus to treat ocular conditions including diabetic macular oedema (DME) and wet age-related macular degeneration (AMD).
Santen Pharmaceutical Co. Ltd. (Japan) and MacuSight Inc. (US) are to collaborate on developing MacuSight's sirolimus to treat ocular conditions including diabetic macular oedema (DME) and wet age-related macular degeneration (AMD).
According to a statement released by the companies, Santen's rights under the new research and development collaboration and license agreement are restricted to Japanese and Asian markets.Santen granted an initial payment of $50 million to MacuSight to continue its sirolimus R&D activities.
The company is currently beginning a Phase II trial of sirolimus, which has multiple mechanisms of action and has been shown to be effective against a wide range of diseases, including DME, and plans to initiate a Phase II wet AMD study later this year.
Phase I trials of subconjunctival and intravitreal administration showed sirolimus to be safe and well-tolerated in AMD and DME subjects, with concomitant improvement in visual acuity.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.